TGFBR1 and breast cancer: TGFBR-1 inhibitor (galunisertib) and anti-PD-L1 combination treatment increased intra-tumoral T cell infiltration and activation, thereby promoting a potent anti-tumor response in CRC and BC pre-clinical models.